HomeIndustriesHealthcareDianthus Therapeutics (DNTH) CEO On Biotech & Merger

Dianthus Therapeutics (DNTH) CEO On Biotech & Merger

Dianthus Therapeutics (DNTH) is a clinical-stage biotech company that develops antibody complement therapeutics. CEO Marino Garcia joins Oliver Renick to discuss DNTH. DNTH completed a merger with Magenta Therapeutics and began trading on the NASDAQ under the ticker “DNTH.” DNTH announced positive top-line phase 1 data for DNTH103 treatment. Tune in to find out more about the stock market today.

Morning Trade Live

15 Sep 2023

SHARE

ON AIR
2:00 pm
Market On Close
12:00 am
Trading 360
REPLAY
1:00 am
Fast Market
REPLAY
2:00 am
Next Gen Investing
REPLAY
education
3:00 am
Your First Trade
REPLAY
education
3:30 am
Inside the Mind of a Trader
REPLAY
education
4:00 am
Inside the Mind of a Trader
REPLAY
education
4:30 am
Inside the Mind of a Trader
REPLAY
education
5:00 am
Your First Trade
REPLAY
education
5:30 am
Your First Trade
REPLAY
6:00 am
Market Overtime
REPLAY
7:00 am
Morning Movers
8:00 am
Morning Trade Live
10:00 am
Trading 360
11:00 am
Fast Market
12:00 pm
Next Gen Investing
1:00 pm
The Watch List
ON AIR
2:00 pm
Market On Close
3:30 pm
Market Overtime
REPLAY
4:30 pm
Market Overtime
REPLAY
5:00 pm
Fast Market
REPLAY
6:00 pm
Next Gen Investing
REPLAY
7:00 pm
Market Overtime
REPLAY
education
8:00 pm
Your First Trade
REPLAY
education
8:30 pm
Your First Trade
REPLAY
9:00 pm
Market Overtime
REPLAY
education
10:00 pm
Inside the Mind of a Trader
REPLAY
education
10:30 pm
Inside the Mind of a Trader
REPLAY
education
11:00 pm
Inside the Mind of a Trader
REPLAY
education
11:30 pm
Your First Trade
REPLAY

Schwab Network's Newsletters

Daily insights for every investor